The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine
Abstract
BACKGROUND: Cyclosporine (INN, ciclosporin) increases the systemic exposure of all statins. Therefore rosuvastatin pharmacokinetic parameters were assessed in an open-label trial involving stable heart transplant recipients (> or =6 months after transplant) on an antirejection regimen including cyclosporine. Rosuvastatin has been shown to be a substrate for the human liver transporter organic anion transporting polypeptide C (OATP-C). Inhibition of this transporter could increase plasma concentrations of rosuvastatin. Therefore the effect of cyclosporine on rosuvastatin uptake by cells expressing OATP-C was also examined. METHODS: Ten subjects were assessed while taking 10 mg rosuvastatin for 10 days; 5 of these were then assessed while taking 20 mg rosuvastatin for 10 days. Rosuvastatin steady-state area under the plasma concentration-time curve from time 0 to 24 hours [AUC(0-24)] and maximum observed plasma concentration (Cmax) were compared with values in controls (historical data from 21 healthy volunteers taking 10 mg rosuvastatin). Rosuvastatin uptake by OATP-C-transfected Xenopus oocytes was also studied by use of radiolabeled rosuvastatin with and without cyclosporine. RESULTS: In transplant recipients taking 10 mg rosuvastatin, geometric mean values and percent coefficient of variation for steady-state AUC(0-24) and Cmax were 284 ng. h/mL (31.3%) and 48.7 ng/mL (47.2%), respectively. In controls, these values were 40.1 ng. h/mL (39.4%) and 4.58 ng/mL (46.9%), respectively. Compared with control values, AUC(0-24) and Cmax were increased 7.1-fold and 10.6-fold, respectively, in transplant recipients. In transplant recipients taking 20 mg rosuvastatin, these parameters increased less than dose-proportionally. Rosuvastatin had no effect on cyclosporine blood concentrations. The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8.5 +/- 1.1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2.2 +/- 0.4 micromol/L when the rosuvastatin concentration was 5 micromol/L). CONCLUSIONS: Rosuvastatin exposure was significantly increased in transplant recipients on an antirejection regimen including cyclosporine. Cyclosporine inhibition of OATP-C-mediated rosuvastatin hepatic uptake may be the mechanism of the drug-drug interaction. Coadministration of rosuvastatin with cyclosporine needs to be undertaken with caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
König, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.1.g156 · Cited by 620
Myers, G. L., Cooper, G. R., Winn, C. L., & Smith, S. J. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30645-0 · Cited by 404
Shitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
Hebert, M. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00043-4 · Cited by 288
Metabolism, Excretion, and Pharmacokinetics of Rosuvastatin in Healthy Adult Male Volunteers
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80336-3 · Cited by 286
Nakai, D., Nakagomi, R., Furuta, Y., Tokui, T., Abe, T., Ikeda, T., & Nishimura, K. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29609-9 · Cited by 217
benefit-risk assessment of Rosuvastatin 10 to 40 milligrams
Brewer, H. B. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00779-3 · Cited by 198
Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers
Martin, P. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80316-8 · Cited by 191
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Ho, R. H., Tirona, R. G., Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y., & Kim, R. B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.034 · Cited by 611
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
Transporters as a determinant of drug clearance and tissue distribution
Shitara, Y., Horie, T., & Sugiyama, Y. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.003 · Cited by 496
LEE, E., RYAN, S., BIRMINGHAM, B., ZALIKOWSKI, J., MARCH, R., AMBROSE, H., MOORE, R., LEE, C., CHEN, Y., & SCHNECK, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 432
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Huang, S., Strong, J. M., Zhang, L., Reynolds, K. S., Nallani, S., Temple, R., Abraham, S., Habet, S. A., Baweja, R. K., Burckart, G. J., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312153 · Cited by 396
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009290 · Cited by 302
Noé, J., Portmann, R., Brun, M.-E., & Funk, C. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012930 · Cited by 291
Predicting Drug–Drug Interactions: An FDA Perspective
Zhang, L., Zhang, Y., Zhao, P., & Huang, S.-M. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9106-3 · Cited by 267
Role of OATP Transporters in the Disposition of Drugs
Niemi, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.787 · Cited by 266
Elsby, R., Hilgendorf, C., & Fenner, K. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.163 · Cited by 198
Impact of genetic variation in OATP transporters to drug disposition and response
Gong, I. Y., & Kim, R. B. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rv-099 · Cited by 137
Drug interactions evaluation: An integrated part of risk assessment of therapeutics
Zhang, L., Reynolds, K. S., Zhao, P., & Huang, S.-M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.016 · Cited by 125
“…[Fexofenadine] Labeling, http://www.accessdata.fda.gov/drugsatfda_ docs/label/2008/020872s018,021963s002lbl.pdf), rosuvastatin and cyclosporin (Simonson et al., 2004) (CRESTOR [Rosuvastatin] Labeling, http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/ 021366s017lbl.pdf), penicillin and…”
BackgroundInfluentialVan Der Lee, M., Sankatsing, R., Schippers, E., Vogel, M., Fätkenheuer, G., Van Der Ven, A., Kroon, F., Rockstroh, J., Wyen, C., Bäumer, A., et al. (2007) · Antiviral Therapy · doi:10.1177/135965350701200711 · Cited by 78
Barton, H. A., Lai, Y., Goosen, T. C., Jones, H. M., El-Kattan, A. F., Gosset, J. R., Lin, J., & Varma, M. V. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759210 · Cited by 68
Efflux and uptake transporters as determinants of statin response
Rodrigues, A. C. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003713519 · Cited by 64
“Despite the fact that statins potentiate the immunosupressant effect of CsA, in cyclosporine-treated patients, the plasma concentrations of statins are greatly increased [90-93] and are related to increased incidence of myopathy when compared to statin monotherapy (0.”
BackgroundConsideraciones específicas en la prescripción e intercambio terapéutico de estatinas
García-Sabina, A., Gulín-Dávila, J., Sempere-Serrano, P., González-Juanatey, C., & Martínez-Pacheco, R. (2012) · Farmacia Hospitalaria · doi:10.1016/j.farma.2011.02.010 · Cited by 17
Metadata
- Authors
- SIMONSON, S.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2004-08
- Volume
- 76
- Issue
- 2
- Pages
- 167-177
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2085448380
- Cited by
- 330
- References
- 27
- FWCI
- 14.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.